臨床検査57巻6号

2013年06月発行

今月の特集1 尿バイオマーカー

尿中L-fatty acid binding proteinによる病態解析

著者： 池森敦子¹ 菅谷健² 松井勝臣² 市川大介² 木村健二郎²

所属機関： ¹聖マリアンナ医科大学腎臓・高血圧内科，解剖学（機能組織） ²聖マリアンナ医科大学腎臓・高血圧内科

ページ範囲：P.623 - P.629

■2011年8月に保険収載された尿中L型脂肪酸結合蛋白（L-FABP）は，尿細管機能障害マーカーである．

■新尿（随時尿）で測定でき，尿クレアチニン補正をした正常上限値は，8.4μg/g.creatinineである．

■糖尿病性腎症を含む慢性腎疾患（CKD）や急性腎不全〔急性腎障害（AKI）〕の早期診断や疾患進行予後予測に優れたモニタリングマーカーである．

参考文献

1）Risdon RA, Sloper JC, De Wardener HE：Relationship between renal function and histological changes found in renal-biopsy specimens from patients with persistent glomerular nephritis. Lancet　2：363-366，1968

2）Sasaki H, Kamijo-Ikemori A, Sugaya T, et al：Urinary fatty acids and liver-type fatty acid binding protein in diabetic nephropathy. Nephron Clin Pract　112：c148-c156，2009

3）Kamijo A, Sugaya T, Hikawa A, et al：Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol　165：1243-1255，2004

4）Kamijo A, Kimura K, Sugaya T, et al：Urinary free fatty acids bound to albumin aggravate tubulointerstitial damage. Kidney Int　62：1628-1637，2002

5）Urahama Y, Ohsaki Y, Fujita Y, et al：Lipid droplet-associated proteins protect renal tubular cells from fatty acid-induced apoptosis. Am J Pathol　173：1286-1294，2008

6）Furuhashi M, Hotamisligil GS：Fatty acid-binding proteins：role in metabolic diseases and potential as drug targets. Nat Rev Drug Discov　7：489-503，2008

7）Kamijo-Ikemori A, Sugaya T, Matsui K, et al：Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrology　16：539-544，2011

8）Kamijo A, Kimura K, Sugaya T, et al：Urinary fatty acid-binding protein as a new clinical marker of the progression of chronic renal disease. J Lab Clin Med　143：23-30，2004

9）Kamijo-Ikemori A, Sugaya T, Yasuda T, et al：Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic patients. Diabetes Care　34：691-696，2011

10）Kamijo A, Sugaya T, Hikawa A, et al：Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease：a multi-center trial. J Lab Clin Med　145：125-133，2005

11）Nielsen SE, Sugaya T, Tarnow L, et al：Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care　32：1684-1688，2009

12）Nielsen SE, Sugaya T, Hovind P, et al：Urinary liver-type fatty acid-binding protein predicts progression to nephropathy in type1 diabetic patients. Diabetes Care　33：1320-1324，2010

13）Nakamura T, Sugaya T, Kawagoe Y, et al：Urinary liver-type fatty acid-binding protein levels for differential diagnosis of idiopathic focal glomerulosclerosis and minor glomerular abnormalities and effect of low-density lipoprotein apheresis. Clin Nephrol　65：1-6，2006

14）Nakamura T, Sugaya T, Kawagoe Y, et al：Candesartan reduces urinary fatty acid-binding protein excretion in patients with autosomal dominant polycystic kidney disease. Am J Med Sci　330：161-165，2005

15）Nakamura T, Sugaya T, Kawagoe Y, et al：Effect of pioglitazone on urinary liver-type fatty acid-binding protein concentrations in diabetes patients with microalbuminuria. Diabetes Metab Res Rev　22：385-389，2006

16）Nakamura T, Sugaya T, Kawagoe Y, et al：Effect of pitavastatin on urinary liver-type fatty acid-binding protein levels in patients with early diabetic nephropathy. Diabetes Care　28：2728-2732，2005

17）Matsui K, Kamijo-Ikemori A, Sugaya T, et al：Usefulness of urinary biomarkers in early detection of acute kidney injury after cardiac surgery in adults. Circ J　76：213-220，2012

18）Nakamura T, Sugaya T, Node K, et al：Urinary excretion of liver-type fatty acid-binding protein in contrast medium-induced nephropathy. Am J Kidney Dis　47：439-444，2006

19） Matsui K, Kamijo-Ikemori A, Hara M, et al：Clinical significance of tubular and podocyte biomarkers in acute kidney injury. Clin Exp Nephrol　15：220-225，2011